Rapid hyperacute intracranial deterioration following initiation of ipilimumab/nivolumab in BRAF V600E-mutant melanoma of unknown primary with brain metastases after BRAF/MEK inhibitor therapy: a case series.

Abstract excerpt

Therapeutic sequencing in BRAF-mutant melanoma with active brain metastases remains clinically challenging. Limited data exist regarding outcomes following transition from BRAF/MEK inhibition to combined immune checkpoint inhibition in patients with melanoma of unknown primary (MUP). We retrospectively reviewed three patients with BRAF V600E-mutant MUP treated at a single tertiary oncology center. All patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Neoplasms
• Share to BRAF gene